Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADMA Biologics, Inc. (NASDAQ: ADMA) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated explanations to help interpret the information. ADMA is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases.
Through this page, users can review ADMA’s current and historical SEC filings, including Form 8-K reports that announce material events such as quarterly financial results and business updates. For example, an 8-K dated November 5, 2025, references a press release detailing financial results for the quarter ended September 30, 2025 and a related business update. Filings such as 10-K annual reports and 10-Q quarterly reports (when available) typically contain detailed information on revenue composition, operating segments such as ADMA BioManufacturing and Plasma Collection Centers, risk factors, and descriptions of products like ASCENIV, BIVIGAM and NABI-HB.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand complex regulatory language. Users can also track real-time updates as new filings are posted to the SEC’s EDGAR system, and review insider transaction disclosures on forms such as Form 4 when they are filed, to see reported trades by company officers and directors.
This SEC filings hub is intended for investors and researchers who want a structured view of ADMA’s regulatory reporting, including its financial performance communications, capital structure updates, and disclosures related to its plasma-derived biologics portfolio and manufacturing operations.
ADMA Biologics COO & SVP, Compliance Kaitlin M. Kestenberg-Messina filed a Form 4 for an automatic share withholding event on 07/24/2025. Transaction code F shows 3,027 common shares were surrendered to the company at $17.31 per share to satisfy payroll-tax obligations triggered by the vesting of restricted stock units (RSUs); no shares were sold on the open market.
Post-transaction, the executive beneficially owns 487,398 ADMA shares, comprised of 192,874 fully vested shares and 294,524 unvested RSUs that vest quarterly through 2029, contingent on continued service.
- The filing is a routine tax-settlement and does not reflect a discretionary reduction in ownership.
- Share count outstanding is modestly reduced, but insider economic exposure is unchanged.
ADMA Biologics (ADMA) Form 4 filing: CFO & Treasurer Brad L. Tade reported an automatic disposition of 7,123 common shares on 07/24/2025 using transaction code “F”, which indicates shares were withheld by the issuer solely to satisfy payroll-tax obligations triggered by restricted-stock-unit (RSU) vesting. The shares were valued at $17.31, an implied $123 k transaction value.
Following the tax withholding, Tade directly owns 239,419 shares. This total includes about 204,027 unvested RSUs granted in 2023-2025 that vest quarterly over four-year periods, plus 35,392 previously acquired shares. No derivative securities were bought or sold, and no open-market activity occurred.
The filing is routine, involves no cash proceeds to the insider, does not alter the company’s share count, and has limited market impact.
Form 4 overview: ADMA Biologics (ticker ADMA) disclosed that Chief Financial Officer & Treasurer Brad L. Tade had 9,838 common shares withheld on 06/26/2025 (transaction code “F”). The “F” code means the shares were automatically surrendered to the company to satisfy statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs); it was not an open-market sale.
Post-transaction holdings: Tade’s stated beneficial ownership is 246,542 shares after the withholding event. This figure comprises:
- 186,127 unvested RSUs spread across four grant dates (June 2023, Feb 2024, July 2024, Feb 2025) that vest quarterly over four years, contingent on continued employment.
- 24,415 fully vested shares accumulated through open-market purchases and past RSU settlements.
- The remaining balance represents fully vested shares already held.
No derivative activity was reported in Table II, and there were no purchases or sales of stock options or other instruments.
Investor takeaway: The filing is routine and signals mandatory tax withholding rather than discretionary selling. Insider equity alignment remains intact; the CFO continues to hold a meaningful stake that will grow as RSUs vest.
ADMA Biologics (ADMA) President and CEO Adam S. Grossman reported multiple transactions on June 16, 2025, executed under a pre-established Rule 10b5-1 trading plan from December 2024. The transactions included:
- Exercise of stock options for 15,000 shares at $5.40 per share
- Sale of 21,000 total shares at $20.81 per share
- Post-transaction direct ownership of 2,043,850 shares
- Indirect ownership of 1,143,426 shares through Areth LLC and 580,957 shares through Hariden LLC
Grossman maintains significant equity positions including unvested RSUs totaling over 1 million shares granted between 2022-2025, vesting quarterly over four years. He also holds 810,950 stock options granted February 2024 at $5.40/share, vesting through February 2028. The transactions demonstrate a routine exercise-and-sell pattern while maintaining substantial long-term ownership.